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A B S T R A C T
Purpose: In the 1970s and 80s, standard treatment for childhood acute lymphocytic leukemia (ALL)
included both intrathecal methotrexate and whole-brain irradiation. During acute treatment, seizures
were not uncommon. The development of intractable epilepsy years after treatment, however, has not
been well described in the literature. We describe ﬁve patients who were treated for acute lymphocytic
leukemia as children, who later developed intractable epilepsy.
Results: All of the patients were diagnosed with leukemia before age seven. Treatment included both
whole-brain irradiation and intrathecal chemotherapy. All ﬁve received intrathecal methotrexate; in
addition, two also received intrathecal cytosine arabinoside. The ﬁrst seizure occurred at a mean of 7.5
years after diagnosis. Four patients have multiple seizure types, and all patients have been on multiple
antiepileptic drugs. All ﬁve patients are cognitively impaired.
Conclusions: Successful treatment for childhood leukemiamay be followed by signs of late cerebral injury
including intractable epilepsy. We propose that neurotoxicity resulting from exposure to intrathecal
methotrexate and cranial irradiation may have contributed to the intractable epilepsy seen in our ﬁve
patients.
Published by Elsevier Ireland Ltd on behalf of British Epilepsy Association.
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Seizures are seen in 8–13% of patients with acute lymphocytic
leukemia (ALL).1 Most seizures occur during the acute treatment
phases of induction and central nervous system consolidation,
which comprise the ﬁrst 6 weeks of remission-inducing treatment.
In a study of 17 patients with ALL who had seizures, all but one of
the patients had the initial seizure during acute treatment; seizure
recurrences were infrequent, and only two of the patients, who
were neurologically abnormal at baseline, developed epilepsy.1
Another study reported that 4 of 30 childrenwith ALLwho had had
a seizure would develop epilepsy; however, etiologies such as
disseminated intravascular coagulopathy, hyponatremia, and
stroke were identiﬁed in three of the four children with epilepsy.2
The development of intractable epilepsy after treatment for
leukemia is less well described, and therefore, the incidence is
unknown. Khan et al. reported six cases of children with atonic* Corresponding author. Present address: National Institutes of Health, 10 Center
Drive, 7-5680 MSC 1404, Bethesda, MD 20892, USA. Tel.: +1 301 443 9995;
fax: +1 301 402 8796.
E-mail address: fasanore@ninds.nih.gov (R.E. Fasano).
1059-1311/$ – see front matter . Published by Elsevier Ireland Ltd on behalf of British
doi:10.1016/j.seizure.2008.10.008seizures who were survivors of childhood ALL. Two of these
children developed intractable epilepsy at least a year after
diagnosis with leukemia, and the other patients developed
epilepsy that was either partly controlled or well-controlled.3
We describe ﬁve adults who developed intractable epilepsy years
after being treated for childhood acute lymphocytic leukemia; we
propose that our patients’ intractable seizures may be related to
their exposure to both intrathecal methotrexate and cranial
irradiation.
2. Methods
Children with a history of acute lymphocytic leukemia were
identiﬁed from the Rush University Epilepsy Center. Institutional
review board permission and written informed consent from
parents were obtained prior to chart review. Charts were reviewed
for age at diagnosis of leukemia; leukemia treatment received,
including chemotherapeutic drugs and radiation; age at ﬁrst
seizure; seizure type(s) and frequency; anti-epileptic treatment
history; electroencephalogram (EEG) ﬁndings; MRI brain ﬁndings;
and cognitive status. Intractable epilepsy was deﬁned as a seizure
frequency of at least once per month.Epilepsy Association.
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3.1. Patient 1
A 25-year-old man was diagnosed with acute lymphocytic
leukemia at age 212. He did not have central nervous systemdisease.
Remission was achieved after induction with vincristine, pre-
dnisone, adriamycin, and daunorubicin. As CNS prophylaxis, he
received intrathecal methotrexate, intrathecal cytosine arabino-
side, and 18 Gray (Gy) cranial irradiation. During the induction
phase, he had a febrile seizure and was subsequently treated with
phenobarbital for 1 year. Hewas seizure-free until age 15, when he
had a staring spell. One week later, he had a generalized tonic-
clonic seizure. Within weeks, he was having six seizures a day. An
EEG showed generalized spike-wave discharges and focal spikes in
the left and right temporal regions. Two MRIs of the brain were
unremarkable. He was treated with numerous antiepileptic
medications (both as monotherapy and in combination), including
phenytoin, valproate, gabapentin, and lamotrigine. Seizure control
was eventually obtained with valproate/lamotrigine combination
therapy. Before diagnosis, he was a gifted student; afterward, he
required placement in a behavior disorder classroom. Neuropsy-
chological testing revealed moderately impaired verbal abilities.
He graduated from high school, but has had difﬁculty retaining
employment.
3.2. Patient 2
A 29-year-old female was diagnosed with acute lymphocytic
leukemia at age 212. There was no CNS disease. She achieved
remission after induction with prednisone, vincristine, L-aspar-
aginase, and methotrexate. She received cranial irradiation and
intrathecal methotrexate as CNS prophylaxis. She had no seizures
during antileukemic treatment. At age 14, she began having daily
complex partial seizures. She had secondarily generalized seizures
several times per year. An EEG showed left temporal epileptiform
discharges. An MRI of the brain revealed multiple areas of high T2
and FLAIR signal in the bilateral cerebral white matter. Seizure
control was poor, despite trials of multiple medications, including
carbamazepine, phenytoin, phenobarbital, lamotrigine, gabapen-
tin, zonisamide, valproate, topiramate, and levetiracetam. After
placement of a vagus nerve stimulator, her seizure frequency
decreased from several seizures per week to 1–2 per month. She
continues to take topiramate and carbamazepine. She required
special education classes in high school. Though she graduated, she
has remained at home with her parents.
3.3. Patient 3
A 27-year-old male was diagnosed with acute lymphocytic
leukemia at age 7. There was no CNS disease. He achieved
remission after induction with vincristine, L-asparaginase, pre-
dnisone, and daunomycin. As CNS prophylaxis, he received
intrathecal methotrexate and cytosine arabinoside; he also
received 18 Gy cranial irradiation. One month after induction,
he went into status epilepticus and was put into a phenobarbital
coma for 5 days. He recovered after a prolonged ICU stay and was
seizure-free for 3 years. At age 10, he began having complex partial
seizures three times a week. An EEG showed epileptiform
discharges in the left and right temporal regions. An MRI of the
brain was unremarkable. He was treated with multiple anti-
epileptic drugs, including phenytoin, valproate, phenobarbital,
tiagabine, oxcarbazepine, zonisamide, topiramate, gabapentin, and
levetiracetam. Seizures continue at a frequency of 1–2 per month
on phenytoin and levetiracetam. Before he developed epilepsy, hewas an average student; however, he subsequently required
special tutoring in high school. Neuropsychological testing showed
borderline intellectual ability with diffuse cognitive impairment.
3.4. Patient 4
A 27-year-old female was diagnosed with acute lymphocytic
leukemia at age 3. There was no CNS disease. Remission was
achieved after induction with vincristine, L-asparaginase, pre-
dnisone, and daunorubicin. She received intrathecal methotrexate
and 18 Gy cranial irradiation as CNS prophylaxis. She had no
seizures during treatment. Six years after diagnosis, and three
years after she ﬁnished chemotherapy, she began having seizures.
She had several different types, including staring spells, atonic
seizures, and generalized tonic-clonic seizures. Her EEG showed
multifocal epileptiform activity and generalized spike-wave
discharges. An MRI of the brain showed increased T2 signal in
the left mesial temporal lobe. Despite therapy with multiple
antiepileptic drugs, including phenobarbital, phenytoin, ethosux-
imide, valproate, zonisamide, carbamazepine, felbamate, and
gabapentin, she has continued to have daily seizures. A vagus
nerve stimulator did not improve her seizure frequency. She was
unable to attend regular school due to severe cognitive impair-
ment, and ultimately required placement in a long-term care
facility.
3.5. Patient 5
A 26-year-old male was diagnosed with acute lymphocytic
leukemia at age 8 months. There was no CNS disease. Remission
was achieved after induction with vincristine, prednisone, and
daunorubicin. He received intrathecal methotrexate as CNS
prophylaxis. Initially, he did not receive cranial irradiation due
to his young age. At age 212, he was found to have a testicular mass;
biopsy showed sheets of leukemia cells. He was treated with high-
dose cyclophosphamide, thioguanine, cytosine arabinoside, and
adriamycin; he received intrathecal methotrexate and cranial
irradiation. At age 3, he had a generalized seizure 12 h after
cyclophosphamide administration; he was hyponatremic at the
time. He was treated with phenobarbital for 1 week. He was
seizure free until age 9, when he began having daily seizures. He
had multiple types, including complex partial seizures, atonic
seizures, and generalized tonic-clonic seizures. At times he had up
to 100 seizures per day. His EEG showed bifrontal epileptiform
discharges. A brain MRI showed subtle areas of high signal in the
periventricular white matter on T2 and FLAIR. He was tried on
multiple medications, including phenytoin, valproate, carbama-
zepine, lamotrigine, levetiracetam, oxcarbazepine, felbamate,
tiagabine, topiramate, and zonisamide. The ketogenic diet did
not improve seizure frequency. He required special education in
school due to severe cognitive deﬁcits, and requires full-time care
in an assisted living facility.
4. Results
Clinical and demographic data are summarized in Table 1. In
our clinic, a tertiary care referral center, ﬁve patients with
intractable epilepsy and a history of childhood leukemia were
identiﬁed. The mean age at diagnosis of leukemia was 212 years old.
None of the children had or developed central nervous system
disease. As CNS prophylaxis, all of the children received both
cranial irradiation and intrathecal chemotherapy; all received
intrathecal methotrexate, and two received intrathecal cytosine
arabinoside as well. All of the children achieved remission from
leukemia; one child (patient 5) had a testicular relapse 22 months
Table 1
Patient data.
Patient/age/age
at ALL Dx:
CNS prophylaxis received Interval to
development
of epilepsy
Seizure
type(s)
EEG MRI Number of AEDs tried;
non-pharmacologic tx
tried
Follow-up
1/25 y/2.5 y Intrathecal methotrexate 12.5 y CPS Multifocal epileptiform
discharges
Unremarkable 4 Good control (6 sz/year) with
valproic acid/lamotrigine
Intrathecal ara-C Absence 3 Hz spike-and-wave
discharges
18 Gy cranial irradiation GTC
2/29 y/2.5 y Intrathecal methotrexate 11.5 y CPS Left temporal epileptiform
discharges
High T2 and FLAIR
signal in white matter
diffusely and at the
gray-white junction
9 Fair control (1–2 sz/mth) with
VNS, topiramate, and
carbamazepine
18 Gy cranial irradiation 20 GTC
Vagus nerve stimulator
3/27 y/7 y Intrathecal methotrexate 3 y CPS Bilateral frontotemporal
epileptiform discharges
Unremarkable 9 Fair control (1–2 sz/mth) on
phenytoin and levetiracetam
Intrathecal ara-C
18 Gy cranial irradiation
4/27 y/3 y Intrathecal methotrexate 6 y CPS Multifocal epileptiform
discharges
Increased signal L
mesial temporal lobe
8 Poor control; daily seizures
18 Gy cranial irradiation Atonic Generalized spike-and-wave
GTC Vagus nerve stimulator
5/26 y/2.5 y Intrathecal methotrexate 6.5 y CPS Bifrontal discharges High T2 and FLAIR
signal in white matter
10 Poor control; daily seizures
18 Gy cranial irradiation Absence Generalized spike-and-wave
Atonic Ketogenic diet
GTC
R
.E
.
Fa
sa
n
o
,
D
.C
.
B
erg
en
/Seizu
re
1
8
(2
0
0
9
)
2
9
8
–
3
0
2
3
0
0
R.E. Fasano, D.C. Bergen / Seizure 18 (2009) 298–302 301after diagnosis and was treated with a second round of
chemotherapy, including intrathecal methotrexate.
The mean age at ﬁrst seizure was ten years old. Four patients
have multiple seizure types, and all have been treated with
multiple anti-epileptic drugs. Two patients had vagus nerve
stimulators placed (one of which experienced a beneﬁt), and
one patient unsuccessfully tried the ketogenic diet. Seizure control
has been poor in these patients; all but one have seizures at least
once a month, and two patients have daily seizures. All of the
patients are cognitively impaired; two required placement in long-
term care facilities, and the other three are unable to live
independently.
5. Discussion
Until the 1980s, conventional treatment for childhood leukemia
involved prophylaxis against central nervous system disease using
both cranial irradiation and intrathecalmethotrexate.4 Though this
treatment regimen greatly increased survival among leukemia
patients, reports of neuropsychological late effects eventually led
to a search for prophylaxis protocols with lower neurotoxic
potential. In 1982, the combination of cranial irradiation and
intrathecal methotrexate was abandoned in favor of intrathecal
methotrexate alone.4 Our patients all received both intrathecal
methotrexate and cranial irradiation; two patients received
intrathecal cytosine arabinoside as well. We hypothesize that
our patients’ intractable seizures may be related to their exposure
to these neurotoxic agents.
Methotrexate has been used as a chemotherapeutic agent for
many years. A dihydrofolate reductase inhibitor, its use leads to
depletion of folate.5 This affects several biochemical pathways,
resulting in decreased synthesis of nucleic acids. This mechanism
is responsible for both the therapeutic and toxic effects of the drug.
When given intrathecally, methotrexate is associated with a wide
range of neurotoxic effects, including acute seizures, encephalo-
pathy, stroke-like episodes with focal neurologic deﬁcits, and
chronic cognitive impairment.6 Imaging studies have shownwhite
matter changes in patients who have received intrathecal
methotrexate, and diffusion-weighted MRI abnormalities have
also been described.2
The neurotoxic effects ofmethotrexate are not fully understood,
and are likely multifactorial. Methotrexate administration causes
folate deﬁciency and elevated levels of homocysteine.5 This
hyperhomocysteinemia has been implicated in the pathogenesis
of methotrexate neurotoxicity, as homocysteine is known to cause
vascular endothelial injury.7,8 This may explain the stroke-like
episodes and focal neurologic deﬁcits that have been described
with methotrexate use.9
Excess homocysteine may also be involved in the pathogenesis
of seizures after treatment with methotrexate. Excess homo-
cysteine is metabolized to sulfur-containing amino acids, such as
homocysteic acid (HCA) and cysteine sulﬁnic acid (CSA). These
substances are endogenous NMDA receptor agonists, causing
enhancement of glutamate release.10 Excess levels of glutamate,
the principal excitatory neurotransmitter in the brain, have been
found in epileptogenic foci.11 One case report showed elevated
levels of homocysteine, HCA, and CSA in the cerebrospinal ﬂuid of a
child with acute lymphocytic leukemia who had had a generalized
tonic-clonic seizure 4 days after receiving intrathecal methotrex-
ate.12 Another recent study showed that glutamate uptake and
clearance by astrocytes was decreased by 20–30% in cortical slices
of mice who had had seizures after receiving intrathecal
methotrexate.13 Thus, glutamate excess, the end result of
homocysteine metabolites, may be the cause of seizures after
methotrexate administration.The patients we describe developed intractable epilepsy several
years after receiving intrathecalmethotrexate. Glutamate excess is
known to cause excitotoxicity and eventual neuronal death
through calcium inﬂux, which is triggered by glutamate receptor
activation.14 This is thought to be a mechanism of some epilepsies
and of various neurodegenerative disorders, and may be a
mechanism of our patients’ epilepsy.
Two of our patients also received intrathecal cytosine arabino-
side. A nucleoside analog, its mechanism involves inhibition of
DNA and RNA synthesis. Neurotoxic signs include ataxia,
encephalopathy, myelopathy, and seizures; the mechanism of
neurotoxicity is not well understood.15 Patients who experience
seizures usually do so acutely; one case report described two
patients who had seizures within 24 h of intrathecal cytosine
arabinoside administration. Within 24 h the seizures had resolved,
and neither patient had permanent neurological deﬁcits.16
Using intrathecal cytosine arabinoside in conjunction with
intrathecal methotrexate and radiation may be more neurotoxic
than using cytosine arabinoside alone.17 One case series described
ﬁve children with acute lymphocytic leukemia or Burkitt’s
lymphoma who received intrathecal methotrexate, intrathecal
cytosine arabinoside, and radiation; all of the children developed
necrotizing leukoencephalopathy. Three had progressive ence-
phalopathy, seizures, and death; at autopsy, necrosis, demyelina-
tion, and axonal damage atypical of radionecrosis were seen.17 The
authors suggested that the combination of intrathecal chemother-
apeutic agents and radiation intensiﬁed neurotoxicity; however,
the role of cytosine arabinoside in this process is not well
understood.17
All of our patients also received whole-brain irradiation.
Radiation exerts its effects by causing breakage of DNA strands
in rapidly dividing cells; because they do not replicate, most
neurons are not radiation sensitive. However, the neurons in the
hippocampal area, where neurogenesis continues throughout life,
are exquisitely sensitive to radiation damage.18 Glial and vascular
endothelial cells, which continue to proliferate throughout life, are
also sensitive to the effects of radiation.19
Radiation toxicity can present clinically at many stages of
treatment. Acute, early-delayed, and late-onset encephalopathy
are characterized by headache, focal neurologic deﬁcits, and
transient or severe cognitive impairment; areas of contrast
enhancement, white matter changes, and atrophy (in late-onset
encephalopathy) are seen on CT and MRI images. Histologically,
diffuse demyelination, axonal loss, necrosis, and spongiosis are
seen.20
All of our patients received whole-brain irradiation in
conjunction with intrathecal methotrexate. Though a rare cause
of seizures when given alone, radiation likely potentiates the
neurotoxic effects of methotrexate and other chemotherapeutic
agents. Damage to vascular endothelial cells leads to increased
permeability of the blood–brain barrier (BBB)with resulting higher
concentrations of intravenous chemotherapeutic agents in the
CNS.21,22 The mechanism for such potentiation is less clear when
the chemotherapeutic agents are given intrathecally.
Four of our patients had evidence of temporal lobe irritability
on EEG; it is possible that these vulnerable areaswere damaged by
radiation. Studies of animal models have shown that radiation
causes increased apoptosis, a decrease in cell proliferation, and a
decrease in stem cell differentiation into neurons within the
neurogenic region of the hippocampus18,23–25; this damage may
be the cause of the cognitive deﬁcits that are the hallmark of late-
onset radiation encephalopathy. Such radiation-induced tem-
poral lobe damage, followed bymethotrexate-induced glutamate
excess and excitotoxicity, may explain our patients’ intractable
epilepsy.
R.E. Fasano, D.C. Bergen / Seizure 18 (2009) 298–3023026. Conclusions
Successful treatment for childhood leukemia may be followed
by late signs of neurotoxicity, including intractable epilepsy.
Methotrexate damages the central nervous system by several
mechanisms, including homocysteine-induced vascular endothe-
lial injury and the buildup of sulfur-containing amino acids. Cranial
irradiation damages neurons in the hippocampus, where neuro-
genesis continues throughout life. The neurotoxic damage caused
by intrathecal chemotherapy and cranial irradiation likely con-
tributed to the development of intractable epilepsy in our ﬁve
patients.
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